Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of Orismilast and Midazolam in Healthy Men
NCT03126578Phase 1Completed
- Sponsor
- LEO Pharma
- Start
- May 2017
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of orismilast in psoriasis, atopic dermatitis (AD) and hidradenitis suppurativa (HS), sponsored by LEO Pharma. Primary endpoints: Area Under the Curve from time zero to last measurable concentration at Day 17 and Maximum Plasma Concentration at Day 17. Started May 2017; status: completed.
02
Drugs
orismilast
03
Conditions
psoriasisatopic dermatitis (AD)hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT03126578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126578.